• 1-800-880-6491

Pharma

Partner with MCI-AxialBridge to access our fully integrated de-risking, investor relations, and capital access platform for pharmaceutical (Pharma) companies

Contact UsSubscribe
Investor Sentiment Snapshot

BioPharma

Investor Sentiment Analysis

BioPharma

Over much of the last three years the pharmaceutical sector has lagged the broader market as measured by the S&P 500, a common feature of lower beta sectors during bull markets. However, since the Trump administration’s tariffs and corresponding market volatility, we have seen a marked improvement in performance for Pharma companies on the stock market as investors rotate to more defensive sectors, not withstanding the negative impacts of ongoing turmoil in the Food and Drug Administration’s regulatory processes.

Investor sentiment in the global pharmaceutical sector for 2026 continues to be propelled by the “GLP-1 effect,” which has helped boost projected research and development returns, masking underlying pressures across other therapeutic categories. Consequently, recent global funding trends reveal a highly selective appetite, with capital flowing disproportionately toward late-stage, data-rich assets and companies boasting at least eighteen months of cash runway.

The BioPharma Sector's

Challenges

The global pharmaceutical sector faces a convergence of severe structural bottlenecks and operational headwinds, fundamentally challenged by a historic patent cliff threatening over $300 billion in revenue by 2030. Simultaneously, research and development productivity remains stagnant, with the average cost to develop a single novel asset surging to $2.8 billion. This financial strain is exacerbated by pervasive clinical trial delays stemming from acute participant shortages and complex protocol designs. Regulatory environments are also tightening across key markets, featuring aggressive price negotiations under the U.S. Inflation Reduction Act, stringent generic substitution mandates in Canada, and post-Brexit compliance dualities in the UK. Furthermore, critical supply chain vulnerabilities, partly brought on by geopolitical tariff volatility are fracturing fragile global manufacturing networks and specialized logistics.

The BioPharma Sector's

Opportunities

Emerging opportunities in the global pharmaceutical sector are anchored by high-value therapeutic frontiers, notably the expansive obesity market projected to surpass $120 billion by 2030, alongside next-generation oncology modalities like antibody-drug conjugates and precision immunology. To accelerate these breakthroughs, companies are aggressively integrating artificial intelligence across the research and development continuum, with agentic AI and federated learning platforms expected to compress clinical timelines by up to forty percent and unlock over $60 billion in novel revenue streams. Fueling this accelerated innovation requires immense capital, prompting a structural shift toward non-dilutive financing vehicles such as synthetic royalties. This modality empowers pharma companies to retain operational control while securing essential launch capital, a strategy now favored by nearly eighty-seven percent of surveyed industry executives navigating tighter equity markets.

Implications for your

Investor Relations & Capital Markets Strategy

In the current environment, the investor relations of pharmaceutical companies must evolve to meet heightened expectations around transparency, access, and strategic clarity. Investors expect issuers to demonstrate disciplined capital deployment, especially following recent criticisms of bloated pipelines and misaligned acquisitions. With U.S. drug pricing under political scrutiny and Canadian firms operating within publicly funded healthcare systems, IR teams must clearly articulate pricing/reimbursement strategies, access pathways, and economic potential.

From a capital markets strategy perspective, companies must tailor their investor engagement to align with shifting preferences—emphasizing risk-adjusted returns, milestone visibility, defined end-points, and differentiated pipelines. Investors are scrutinizing regulatory pathways, particularly in light of recent shakeups in U.S. public health leadership. Clear communication around regulatory submissions, advisory committee outcomes, and health economics data will enhance investor confidence.

Given continued interest in partnerships, strategic licensing deals, and bolt-on acquisitions, IR must ensure management communicates how such transactions enhance long-term value. Pharma companies should consider dual-listing strategies and cross-border roadshows to attract  institutional capital from a diverse set of jurisdictions. Consistent messaging across investor materials, press releases, and corporate presentations is essential to building trust in this complex and dynamic sector.

Our Capabilities
MCI Capabilities

Activist Resolution

MCI Capabilities

Corporate Communications

MCI Capabilities

Capital Markets
Strategy

MCI Capabilities

Crisis
Communications

MCI Capabilities

Debt and Equity
Offerings

MCI Capabilities

Financial
Reporting

MCI Capabilities

Design &
Branding

MCI Capabilities

Digital
Technologies

MCI Capabilities

ESG &
Sustainability

MCI Capabilities

Investor Perception
Studies

MCI Capabilities

Initial Public
Offerings

MCI Capabilities

Ongoing Investor
Relations

MCI Capabilities

Investment
Grade Events

MCI Capabilities

Market
Coaching

MCI Capabilities

Market
Connect

MCI Capabilities

Market
Turnaround

MCI Capabilities

Transaction
Communications

Learn more about the capital markets

Access Our Insights

MCI Capital Markets and AxialBridge to Deliver Integrated De-risking and Capital Access Platform for Life Science Companies

MCI and AxialBridge to Deliver Integrated De-risking and Capital Access Platform for Life Science Companies

 MCI and AxialBridge to Deliver Integrated De-risking and Capital Access Platform for Life Science Companies 1024 576 Tom McMillan

The MCI – AxialBridge partnership will make complex science investable by providing a single, coordinated pathway from bench to bedside to balance sheet.

MCI Capital Markets Presents for the TMX Alpha Catalyst Series - Part of the TSX IR Accelerator 2026

TSX IR Accelerator 2026

 TSX IR Accelerator 2026 1024 576 Tom McMillan

MCI Capital Markets is proud to be a presenting partner for TMX Group‘s launch of Alpha Catalyst: TSX IR Accelerator 2026 for Toronto Stock Exchange and TSX Venture Exchange companies.

Strategies for when Activists Investors are Stalking You

How do you address an activist investor stalking your company?

 How do you address an activist investor stalking your company? 1024 576 Tom McMillan

Are you being stalked by an activist investor quietly accumulating your stock? This guide shows how to respond. From identifying activists early, using stock surveillance to monitor their activity, and engaging with activists constructively, learn how preparation, open communication, and proactive strategy tweaks can turn an activist threat into an opportunity for positive change.

Post Davos 2026 Investor Strategies

In the Aftermath of Davos 2026, How Should Companies Adapt Their Investor Strategy?

 In the Aftermath of Davos 2026, How Should Companies Adapt Their Investor Strategy? 1024 576 Todd Coakwell

Companies must adapt their capital markets and investor strategies post Davos 2026. Davos clarified the risks investors must now actively price, from geopolitical exposure and trade volatility to capital allocation discipline. This article explains what changed at Davos and how global companies should adapt their disclosure and capital markets strategy to maintain credibility, manage investor expectations, and protect valuation.

The Death of Sustainability and ESG

Is Sustainability Dead or Has the Market Simply Moved On?

 Is Sustainability Dead or Has the Market Simply Moved On? 1024 576 Todd Coakwell

Is sustainability dead? Not exactly. While ESG narratives and public commitments have pulled back, capital markets still rely on sustainability data through risk, governance, and financial lenses. This article explains why sustainability has reset, how regulators slowed momentum, and what investors, banks, analysts, and IR teams still need today.

How Should Public Companies Prepare to Raise Capital in the Public Markets?

How To Prepare to Raise Capital in the Public Markets

 How To Prepare to Raise Capital in the Public Markets 1024 576 Tom McMillan

Raising capital in the public markets can unlock new growth for an established company. However, success requires diligent preparation and strategy. This post outlines how public companies can prepare effectively – from defining the use of proceeds and planning the raise, choosing between equity vs debt, tailoring investor communications, building key relationships, and executing a capital raise with confidence.

Stock Splits and Consolidations (Reverse stock splits)

Stock Splits and Consolidations – The Risks and Benefits to Capital Market Performance

 Stock Splits and Consolidations – The Risks and Benefits to Capital Market Performance 1024 576 Tom McMillan

Stock splits and reverse stock splits do not create value on their own. However, they play an important role in how public companies manage liquidity, accessibility, and investor perception. This article explains when stock splits and share consolidation make sense, the risks involved, and how boards and management teams should frame these decisions within a broader capital markets strategy.

Returning Capital to Shareholders

Returning Capital to Shareholders: Dividends, Special Payouts, and Share Buybacks

 Returning Capital to Shareholders: Dividends, Special Payouts, and Share Buybacks 1024 576 Todd Coakwell

Returning capital to shareholders is a key part of a public company’s capital markets strategy. After funding growth and operations, management must decide how to give excess cash back to shareholders as part of their value creation plan. In this post, we explain the main ways of returning capital to shareholders – regular dividends, special…

Implementing AI in your capital markets function

Implementing Artificial Intelligence in Your Capital Markets Program

 Implementing Artificial Intelligence in Your Capital Markets Program 1024 576 Tom McMillan

Artificial intelligence has already become table stakes for corporate capital market functions. Laggards in adopting AI are already watching their valuation lag behind companies that are taking advantage of the efficiency, scale, and enhanced engagement made possible by AI.

Contact Us

The capital markets can be bewildering, even to the most experienced management teams. We believe that most executives are committed to maximizing shareholder value, but poorly executed investor relations can lead to valuation loss, reputational damage, employee attrition, deal failure, and even shareholder revolt.

MCI has helped its clients unlock billions of dollars in market value through a proven system that delivers sound messaging, branding, and engagement strategies. Over the past two decades our team has been involved in $5.7 billion in corporate actions that include $3.1 billion in acquisitions and $2.6 billion in financings-all successful.

MCI can help you resolve unfair valuation discounts and get the most out of your company’s public listing. Contact us today to engage our data driven, results focused process to unleash real progress.